HIV, Buprenorphine, and the Criminal Justice System

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 23, 2012

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2016

Conditions
Human Immunodeficiency VirusAcquired Immunodeficiency SyndromeOpiate AddictionDrug Dependence
Interventions
DRUG

Buprenorphine/naloxone

2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.

DRUG

Placebo Oral Tablet

2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.

Trial Locations (1)

20060

Howard University, Washington D.C.

All Listed Sponsors
collaborator

George Mason University

OTHER

collaborator

Howard University

OTHER

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Yale University

OTHER

NCT01550341 - HIV, Buprenorphine, and the Criminal Justice System | Biotech Hunter | Biotech Hunter